<PAGE>



                   SECURITIES AND EXCHANGE COMMISSION
                         Washington, D.C. 20549

                                FORM 10Q

(X)           QUARTERLY REPORT UNDER SECTION 13 OR 15 (d)
                OF THE SECURITIES EXCHANGE ACT OF 1934

                 For the quarter ended February 28, 1997

                                   OR

( )  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE
                     SECURITIES EXCHANGE ACT OF 1934

           For the transition period from ________ to________

Commission File Number: 0-12665
_______________________________

                         MICRO BIO-MEDICS, INC.
    __________________________________________________________
         (Exact name of Registrant as specified in its charter)

      New York                            13-2692560
______________________________________________________________________
(State or other jurisdiction       (I.R.S. Employer Identification No.)
of incorporation or organization)

846 Pelham Parkway
______________________
Pelham Manor, New York                                         10803
______________________                                         ______
(Address of principal executive offices)                    (Zip Code)

 Registrant's telephone number,
including area code                                   (914) 738-8400
                                                      _______________


____________________________________________________________________
          (Former name, former address and former fiscal year,
                      if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15 (d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period
that the registrant was required to file such reports) and (2) has been
subject to such filing requirements for the past 90 days.


                          Yes  X     No
                              ____      ____

The number of shares of Registrant's Common Stock, par value $.03 per
share outstanding as of April 3, 1997 was 5,092,171


                                 - 1 -


<PAGE>

                 MICRO BIO-MEDICS, INC. AND SUBSIDIARIES

                      QUARTERLY REPORT ON FORM 10-Q

                 FOR THE QUARTER ENDED FEBRUARY 28, 1997

                                  INDEX
                                  _____


                                                                 Page
                                                                Number
                                                                _______


Part I Financial Information

   Item 1. Financial Information
           Consolidated Statements of Operations -
           Three Months Ended February 28, 1997 (Unaudited)
           and February 29, 1996 (Unaudited)                         3

           Consolidated Balance Sheets -
           February 28, 1997 (Unaudited) and November 30, 1996      4-5

           Consolidated Statements of Cash Flows
           Three Months Ended February 28, 1997 (Unaudited)
           and February 29, 1996 (Unaudited)                        6-7

           Notes to Consolidated Financial Statements (Unaudited)    8

   Item 2. Management's Discussion and Analysis of Financial
           Condition and Results of Operations                      9-10


Part II                                                              11

Signature Page                                                       12


                               - 2 -

<PAGE>


                    MICRO BIO-MEDICS, INC. AND SUBSIDIARIES
                      CONSOLIDATED STATEMENT OF OPERATIONS
                                ( UNAUDITED )
        
                                             Three Months Ended
                                         ---------------------------
                                         February 28,    February 29,
                                            1997            1996
                                         ------------    ------------

NET SALES                                $38,004,627     $29,887,421 
COST OF GOODS SOLD                        30,670,850      23,591,909 
                                         -----------     -----------
GROSS PROFIT                               7,333,777       6,295,512 
                                         -----------     -----------
OPERATING EXPENSES       
   Selling, shipping and warehouse         4,501,452       3,823,293 
   General and administrative              2,355,750       2,006,500 
   Interest and financing costs       
    (net of interest income of $ 45,251       
    in 1997, $ 35,728 in 1996)                99,739         314,103 
                                         -----------     -----------
   Total operating expenses                6,956,941       6,143,896 
                                         -----------     -----------
INCOME BEFORE INCOME TAXES                   376,836         151,616 
       
PROVISION FOR INCOME TAXES                   158,300          63,700 
                                         -----------     -----------
NET INCOME                               $   218,536     $    87,916
                                         ===========     ===========
EARNINGS PER COMMON AND       
COMMON EQUIVALENT SHARE                  $      0.04     $      0.02
                                         ===========     ===========
NUMBER OF SHARES USED IN            
COMPUTING EARNINGS PER COMMON          
AND COMMON EQUIVALENT SHARE                6,149,343       5,499,024
                                         ===========     ===========
DIVIDENDS PER COMMON SHARE                  None            None
                                         ===========     ===========

       The notes to financial statements are made a part hereof.


                                         -3-

<PAGE>

       
                   MICRO BIO-MEDICS, INC. AND SUBSIDIARIES
                        CONSOLIDATED BALANCE SHEETS    
                       ------------------------------
       
                                    ASSETS
                                 ------------
       
        
                                              February 28,  
                                                  1997       November 30,
                                              (UNAUDITED)        1996  
                                              ------------   ------------
CURRENT ASSETS          
 Cash                                         $   354,864    $ 1,513,750
 Accounts receivable, less allowance for        
   doubtful accounts, of $688,475 at February          
   1997 and $686,179 at November 1996          30,694,116     31,280,932
 Inventory                                     15,355,018     13,488,244
 Deferred income taxes                            781,500        781,500
 Prepaid expenses and other current assets        707,329        875,451
 Prepaid income taxes                             263,358        329,918
                                              ------------   ------------
        Total current assets                   48,156,185     48,269,795
         
PROPERTY, PLANT AND EQUIPMENT - at cost         
  net of accumulated depreciation and         
  amortization of $3,709,070 at February 1997       
  and $3,433,070 at November 1996               3,665,123      3,758,348
       
INTANGIBLE ASSETS - net of accumulated       
  amortization of $ 1,262,059 at February 1997       
  and $1,155,260 at November 1996               8,605,198      8,254,087
       
OTHER ASSETS                                      161,586        161,586
                                              ------------   ------------
                                              $60,588,092    $60,443,816
                                              ============   ============


The notes to financial statements are made a part hereof.

                                       - 4 -

<PAGE>

                   MICRO BIO-MEDICS, INC. AND SUBSIDIARIES    
                          CONSOLIDATED BALANCE SHEETS    
                   ---------------------------------------
       
                     LIABILITIES AND STOCKHOLDERS' EQUITY    
                   ---------------------------------------

       
                                              February 28,  
                                                  1997     November 30,
                                              (UNAUDITED)      1996
                                             ------------  ------------
CURRENT LIABILITIES:       
 Current maturities of      
   long term debt                            $   432,755   $   432,755 
 Accounts payable                             19,224,267    17,182,644 
 Accrued expenses and      
   sundry liabilities                          2,116,424     2,542,174 
                                             ------------  ------------

         Total current liabilities            21,773,446    20,157,573 
          
          
LONG-TERM DEBT, net of       
    current maturities                         6,966,659     8,714,567 
       
DEFERRED INCOME TAXES                            179,911       179,911 
                                             ------------  ------------
        Total Liabilities                     28,920,016    29,052,051 
                                             ------------  ------------
          
       
STOCKHOLDERS' EQUITY       
 Preferred stock $ 1.00 par value      
   Authorized-1,000,000 shares      
   no shares issued      -      -  
 Common stock $.03 par value      
   Authorized - 20,000,000 shares      
   Issued     - 5,074,015 in February 1997      
              - 5,062,115 in November 1996       152,220       151,863
Capital in excess of par value                21,011,954    20,954,536 
Retained earnings                             10,505,066    10,286,530 
Less: Cost of 1,167 shares of common       
        stock in treasury                         (1,164)       (1,164)
                                             ------------  ------------
     Total stockholders' equity               31,668,076    31,391,765 
                                             ------------  ------------
                                             $60,588,092   $60,443,816
                                             ============  ============

The notes to financial statements are made a part hereof.

                                       - 5 -

<PAGE>

  MICRO BIO-MEDICS, INC. AND SUBSIDIARIES     
    CONSOLIDATED STATEMENTS OF CASH FLOWS     
    (UNAUDITED)   
       
        
                                                    Three Months Ended  
                                                 --------------------------

                                                 February 28,  February 29,
                                                     1997          1996
                                                 ------------  ------------
CASH FLOWS FROM OPERATING ACTIVITIES:       
       
Net Income                                       $   218,536   $    87,916 
                                                 ------------  ------------
Adjustments to reconcile net income to net       
  cash provided by (used in) operating       
  activities:       
   Expenses not requiring the use of cash:       
     Depreciation and amortization                   382,799       282,711 
     Provision for losses on       
       accounts receivable                             2,296         5,701 
   Changes in assets and liabilities,       
     Accounts receivable                             584,520      (505,445)
     Inventory                                    (1,866,774)      310,648 
     Prepaid expenses and other current       
       assets                                        168,122       (29,315)
     Other assets                                                 (328,226)
     Income taxes                                     66,560        62,154 
     Accounts payable                              2,041,623     1,219,346 
     Accrued expenses and sundry       
       liabilities                                  (425,750)     (216,319)
                                                 ------------  ------------
                                                     953,396       801,255 
                                                 ------------  ------------
NET CASH PROVIDED BY       
   OPERATING ACTIVITIES                            1,171,932       889,171 
                                                 ------------  ------------
CASH FLOWS FROM FINANCING ACTIVITIES:       
     Proceeds from exercise of warrants                             41,022 
     Exercise of employee stock options               57,775        20,125 
     Net repayments under       
        revolving loan agreements                 (2,500,000)   (1,500,000)
     Repayment of long-term debt                    (179,457)     (158,446)
     Proceeds of long term debt                      931,549    
                                                 ------------  ------------
NET CASH USED IN       
  FINANCING ACTIVITIES                           $(1,690,133)  $(1,597,299)
                                                 ------------  ------------


The notes to financial statements are made a part hereof

                                       - 6 -   

<PAGE>

                         MICRO BIO-MEDICS, INC. AND SUBSIDIARIES    
                           CONSOLIDATED STATEMENT OF CASH FLOWS    
                         ---------------------------------------
                                     (CONTINUED)
       
       
       
CASH FLOWS FROM INVESTING ACTIVITIES:       
     Capital expenditures                        $  (182,775)   $  (138,563)
     Payments for intangible assets                 (457,910)      (128,791)
                                                 ------------  ------------
NET CASH USED IN       
        INVESTING ACTIVITIES                        (640,685)      (267,354)
                                                 ------------  ------------
       
NET DECREASE IN CASH                              (1,158,886)      (975,482)
       
CASH-beginning of period                           1,513,750      2,817,285 
                                                 ------------  ------------
CASH-end of period                               $   354,864    $ 1,841,803 
                                                 ============  ============
       
       
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
    Cash paid  for:       
      Interest                                   $   149,851    $   349,831 
                                                 ============  ============
      Income taxes                               $    28,811    $     1,500 
                                                 ============  ============
       
       
BUSINESS ACQUIRED FOR ISSUANCE OF STOCK       
   which is not reflected in the above       
   statement                                                    $ 3,228,004 
                                                               ============
       
       
The notes to financial statements are made part hereof.
       


                                       - 7 -   
       
       
<PAGE>

                 MICRO BIO-MEDICS, INC. AND SUBSIDIARIES
                           NOTES TO FORM 10-Q
                            FEBRUARY 28, 1997
                               (UNAUDITED)
                 _______________________________________


NOTE A

The attached summarized financial information does not include all disclosures
required to be included in a complete set of financial statements prepared in
conformity with generally accepted accounting principles. Such disclosures were
included with the consolidated financial statements of the Company at November
30, 1996, includedin its annual report on Form 10-K. Such statements should be
read inconjunction with the data herein.

NOTE B

The financial information reflects all normal recurring adjustments which, in
the opinion of management, are deemed necessary for a fair presentation of the
results for the interim periods. The results for the interim periods are not
necessarily indicative of the results to be expected for the year.

NOTE C - SUBSEQUENT EVENT

On March 7, 1997, the Company entered into an agreement and plan of merger
whereby HSI Acquisition Corp., a wholly-owned subsidiary of Henry Schein,
Inc.("Schein"), will merge into the Company. The Company will be the surviving
corporation as a subsidiary of Schein. Schein is a marketer of healthcare
products and services to office-based healthcare practitioners including dental
practices and laboratories, physician practices and veterinary clinics in the
North American and European markets. As a result of the transaction, outstanding
shares of the Company's common stock will be exchanged at a rate of .62 shares
of Schein's common stock for each outstanding share of the Company. Existing
options and warrants will be exchanged for Schein's options and warrants at the
same rate. It is intended that the merger shall qualify as a tax free
reorganization for income tax purposes and accounted for as a pooling of
interests for financial reporting purposes. 

The completion of the transaction is subject to approval by the Company's
shareholders and to termination of any waiting period under the
Hart-Scott-Rodino Act, and further, all dissenting shares shall not constitute
more than 9% of the Company's outstanding common stock immediately prior to the
effective date of the merger.

For additional information on this plan of merger reference is made to the
Company's Form 10K for its year ended November 30, 1996.

NOTE D - EARNINGS PER SHARE

Earnings per common and common equivalent share are based on the weighted
average number of common shares and common equivalent shares outstanding during
the period. The modified treasury stock method was utilized to calculate the
dilutive effect of the options and warrants upon the earnings per share data.


                                        - 8 -

<PAGE>

                 MICRO BIO-MEDICS, INC. AND SUBSIDIARIES
                            FEBRUARY 28, 1997
            MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
                   CONDITION AND RESULTS OF OPERATIONS
            __________________________________________________

RESULTS OF OPERATIONS
_____________________

For the three months ended February 28, 1997 net sales increased 27.2%
from the prior year. The increase in net sales resulted from the Company's
increased volume to hospitals, the acquisition of Stone Medical Supply Corp. and
our continuing effort to gain market penetration and sales volume from our
existing customer base and the addition of new customers. For the three months
ended February 28, 1997, the introduction of new products, changing prices and
inflation had no material impact on the Company's operations.

OPERATING EXPENSES
__________________

Gross Profit expressed as a percent of net sales decreased from 21.1% to 19.3%
for the three month period ended February 28, 1997 due to increased sales to
hospitals and changes in the product mix. Selling, shipping and warehouse and
general and administrative expenses expressed as a percent of net sales
decreased 1.5% for the three months ended February 28, 1997 when compared to the
prior period.

INTEREST AND FINANCING COSTS (NET OF INTEREST INCOME)
_____________________________________________________

Interest expense net of interest income expressed as a percent of net sales
decreased .8% for the three months ended February 28, 1997 when compared to the
prior period as a result of using the proceeds from the conversion of
outstanding warrants to decrease long-term debt and decreases in the interest
rates charged by financial institutions.



                                  - 9 -

<PAGE>

                 MICRO BIO-MEDICS, INC. AND SUBSIDIARIES
                            FEBRUARY 28, 1997
            MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
                   CONDITION AND RESULTS OF OPERATIONS
            __________________________________________________




LIQUIDITY AND CAPITAL RESOURCES
_______________________________

During the three months ended February 28, 1997, the Company continued to meet
its cash needs via cash flow from operations and borrowings. During the three
months ended February 28, 1997 and 1996, the Company had an average of
approximately $20,000,000 and $12,300,000, respectively, of unused credit lines
available each month over its normal operating requirements.

For the three months ended February 28, 1997, the Company provided cash from
operating activities. The increase in accounts payable and a decrease in
accounts receivable over and above an increase in inventory contributed to the
Company's cash. For the three months ended February 29, 1996, the Company
provided cash from operating activities.  The increase in accounts payable and a
decrease in inventory over and above an increase in accounts receivable
contributed to the Company's cash. During the three months ended February 28,
1997 and February 29, 1996, the Company's financing activities used cash
principally as a result of repayments of the bank loan under its long-term
credit agreement. During the three months ended February 28, 1997 and February
29, 1996, the Company used cash in investing activities to make capital
expenditures and payments for intangible assets.

Management believes that its working capital of approximately $26,400,000 at
February 28, 1997 provides sufficient liquidity for its short and long term
requirements and that the Company's long term liquidity is not materially
effected by any restrictive covenants contained in the Company's Revolving
Credit Agreement. Further, Management believes that the Company should not
experience a problem in connection with the maintenance of such covenants and
that its $25,000,000 line of credit provides the Company with the resources it
reasonably expects to meet its cash commitments.


                                   - 10 -

<PAGE>

                 MICRO BIO-MEDICS, INC. AND SUBSIDIARIES
                           NOTES TO FORM 10-Q
                            FEBRUARY 28, 1997
                               (UNAUDITED)
                 _______________________________________



Item 6 - Exhibits and Reports on Form 8-K
         _________________________________

         a. Exhibit 11 - Earnings per share

            Exhibit 27 - Financial Data Schedule

         b. No report on Form 8-K was required to be filed by Registrant
            during the quarter ended February 28, 1997.


                                 - 11 -

<PAGE>


                 MICRO BIO-MEDICS, INC. AND SUBSIDIARIES

                               SIGNATURES



Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.


                     MICRO BIO-MEDICS, INC.
                     ______________________
                     Registrant





     Date:  April 8, 1997                       /s/ Bruce J. Haber
            __________________                  __________________________
                                                Bruce J. Haber President
                                                and Chief Executive
                                                Officer





     Date:  April 8, 1997                       /s/ Stuart F. Fleischer    
            __________________                  __________________________
                                                Stuart F. Fleischer    
                                                Vice-President - Finance
                                                and Chief Financial
                                                Officer


                                 - 12 -